The histamine connection was the thing that finally made quercetin click for a lot of women in this community — suddenly the wine intolerance, the new-onset hives, and the worsening allergies all had a plausible thread connecting them to falling estrogen. It's one of those nutrients that doesn't get talked about in the standard perimenopause conversation, and that gap feels like a real missed opportunity.
Learn more about Rose →Quercetin stabilises mast cells — the immune cells that store and release histamine — by inhibiting calcium influx, which is the cellular trigger for histamine release. In vitro studies show it can reduce histamine secretion from mast cells more effectively than cromolyn sodium, a pharmaceutical mast cell stabiliser used as a reference compound. This matters enormously for women whose histamine tolerance is shifting during perimenopause, when mast cell behaviour becomes less predictable.
Estrogen has a complex, dose-dependent relationship with mast cells: it can upregulate mast cell sensitivity and increase histamine release when levels fluctuate, as they do throughout perimenopause. This helps explain why some women develop new reactions to alcohol, certain foods, or environmental triggers during their forties even with no prior history of allergies. Quercetin's mast cell-stabilising action makes it particularly relevant at a time when this system is being disrupted by hormonal variability.
Senescent cells are damaged cells that stop dividing but refuse to die, instead secreting a cocktail of pro-inflammatory signals called the senescence-associated secretory phenotype (SASP). The loss of estrogen during the menopausal transition accelerates senescent cell accumulation in tissues including bone, skin, and the vasculature. Quercetin, often studied alongside dasatinib in preclinical senolytic research, has shown an ability to selectively promote apoptosis in senescent cells, which may help reduce the chronic low-grade inflammation that drives many menopausal symptoms.
Quercetin inhibits NF-κB signalling, one of the master switches for inflammatory gene expression, and also suppresses the production of pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α. These are the same cytokines elevated in postmenopausal women and associated with joint pain, fatigue, brain fog, and increased cardiovascular risk. Because it acts on several inflammatory pathways at once rather than just one, its anti-inflammatory effect is considered broader than many single-target compounds.
As a phytoestrogen, quercetin can bind weakly to both estrogen receptor alpha and beta, with a preference for ERβ — the receptor subtype associated with bone, the brain, and the cardiovascular system. It also appears to inhibit aromatase and influence CYP450 enzymes involved in estrogen detoxification, which could affect the ratio of protective to less-protective estrogen metabolites. The clinical significance of these effects in perimenopausal women has not yet been established in large trials, but the mechanisms are plausible and well-characterised at a molecular level.
Quercetin has been shown in animal studies to inhibit osteoclast activity — the cells responsible for bone breakdown — while promoting osteoblast differentiation, which is the process of building new bone. A small number of human observational studies have found associations between higher dietary flavonoid intake, including quercetin, and better bone mineral density in postmenopausal women. This is an area where the evidence remains preliminary but the mechanism is credible enough that bone health researchers are paying attention.
Multiple meta-analyses of randomised controlled trials have found that quercetin supplementation significantly reduces systolic and diastolic blood pressure, particularly in doses above 500 mg per day and in individuals with hypertension. It also improves endothelial function — the ability of blood vessels to dilate appropriately — which tends to decline as estrogen falls. Cardiovascular risk rises meaningfully after menopause, and quercetin's effects on both blood pressure and vascular function make it one of the more evidence-supported non-hormonal options for this risk domain.
Plain quercetin aglycone is poorly absorbed from the gut, with bioavailability estimates ranging from around 17% to 50% depending on the food matrix or supplement form. Formulations that pair quercetin with bromelain, vitamin C, or lecithin — or that use the quercetin phytosome complex — have demonstrated meaningfully better absorption in pharmacokinetic studies. Women considering quercetin supplementation should look at the formulation on the label rather than simply the milligram dose, since a lower dose in a well-absorbed form will likely outperform a higher dose of poorly absorbed plain powder.
Quercetin inhibits certain CYP3A4 and P-glycoprotein enzymes, which are responsible for metabolising a wide range of drugs including some statins, cyclosporine, and certain antibiotics — meaning it can raise blood levels of these medications to potentially problematic ranges. It may also interact with thyroid hormone replacement and warfarin, and high-dose supplementation is not recommended during pregnancy. Any woman taking prescription medications should speak with a pharmacist or prescriber before adding quercetin at supplemental doses, even though it is widely sold without restriction.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.